Drug Monograph
Lactulose
Kristalose, Constulose, Enulose, Generlac
Pharmacokinetic Profile
Systemic Absorption
Negligible (≤3% urinary excretion)
Metabolism
Colonic bacteria (not hepatic)
Onset of Action
24–48 h (oral laxative effect)
Protein Binding
Not applicable (locally acting)
Molecular Weight
342.30 Da
Clinical Information
Drug Class
Osmotic laxative; ammonia detoxicant
Available Doses
10 g/15 mL solution; 10 g & 20 g powder packets
Route
Oral, Rectal
Renal Adjustment
None required
Hepatic Adjustment
None (used to treat hepatic disease complications)
Pregnancy
No evidence of harm (animal studies); use if benefit outweighs risk
Lactation
Likely compatible (negligible absorption)
Schedule
Prescription (US); OTC in some countries
Generic Available
Yes
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Chronic constipation | Adults | Monotherapy | FDA Approved |
| Portal-systemic encephalopathy (PSE) — prevention and treatment | Adults and pediatric patients | Monotherapy or adjunctive (with rifaximin) | FDA Approved |
Lactulose occupies two distinct therapeutic roles. As a laxative, it is a well-established option for chronic constipation where lifestyle modifications and bulk-forming agents have proven insufficient. In hepatology, it is the cornerstone of hepatic encephalopathy management, recommended as first-line therapy by both the AASLD and EASL. The drug can be given orally, via nasogastric tube, or rectally as a retention enema when the oral route is unavailable.
Off-Label Uses
Pediatric constipation: Lactulose is used in children for functional constipation, though safety and efficacy have not been formally established by the FDA for this indication. Widely supported by clinical practice guidelines (NASPGHAN/ESPGHAN). Evidence quality: Moderate.
Post-hemorrhoidectomy bowel management: Used at 15 mL twice daily starting one day before surgery through five days postoperatively to facilitate soft bowel movements. Evidence quality: Moderate.
Colonic barium retention: Used at 5–10 mL twice daily for 1–4 weeks to facilitate evacuation of retained barium. Evidence quality: Low.
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Chronic constipation — oral solution | 15–30 mL (10–20 g) once daily | 15–30 mL once daily | 60 mL/day (40 g) | Response typically occurs within 24–48 h May mix with water, juice, or milk for palatability |
| Chronic constipation — powder (Kristalose) | 10–20 g once daily | 10–20 g once daily | 40 g/day | Dissolve packet in 120 mL (4 oz) water 10 g powder = 15 mL solution equivalent |
| Hepatic encephalopathy — acute episode (oral) | 30–45 mL (20–30 g) q1h | 30–45 mL TID–QID | Titrate to 2–3 soft stools/day | Hourly dosing until first bowel movement, then reduce to maintenance May use NG tube if aspiration risk present |
| Hepatic encephalopathy — chronic prevention (oral) | 30–45 mL TID–QID | 30–45 mL TID–QID | Titrate to 2–3 soft stools/day | Adjust dose every 1–2 days based on stool output Often combined with rifaximin 550 mg BID for secondary prophylaxis |
| Hepatic encephalopathy — rectal (coma/aspiration risk) | 300 mL in 700 mL water or NS | Repeat q4–6h as needed | Per clinical response | Retain for 30–60 min via rectal balloon catheter; lateral recumbent position Transition to oral as soon as patient can swallow safely |
Pediatric Dosing (Hepatic Encephalopathy)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Infants — hepatic encephalopathy | 2.5–10 mL/day divided TID–QID | Titrate to 2–3 soft stools/day | 10 mL/day | Reduce immediately if diarrhea occurs; discontinue if diarrhea persists |
| Children and adolescents — hepatic encephalopathy | 40–90 mL/day divided TID–QID | Titrate to 2–3 soft stools/day | 90 mL/day | Very limited published data in this population Some guidelines suggest 1–3 mL/kg/day divided |
Clinical Pearl: Titration Target
The therapeutic endpoint for lactulose in hepatic encephalopathy is not a fixed dose but a stool output target of 2–3 soft bowel movements per day. Fewer than two stools per day suggests underdosing, while frank diarrhea indicates overdosing and can worsen encephalopathy by causing dehydration and electrolyte disturbances.
Pharmacology
Mechanism of Action
Lactulose is a synthetic disaccharide composed of galactose and fructose that resists hydrolysis by human intestinal enzymes. It reaches the colon intact, where resident saccharolytic bacteria metabolize it into low-molecular-weight organic acids, principally lactic acid, along with smaller amounts of acetic and formic acids. This colonic fermentation produces two clinically useful effects. First, the resulting acidification of colonic contents converts freely diffusible ammonia (NH3) into the non-absorbable ammonium ion (NH4+), effectively trapping ammonia within the intestinal lumen. Second, the accumulated organic acids and undigested sugar create a significant osmotic gradient that draws water into the colonic lumen, increasing stool volume and stimulating peristalsis. The net result in hepatic encephalopathy is a 25–50% reduction in blood ammonia concentration, while in constipation the osmotic effect alone promotes laxation.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Poorly absorbed; ≤3% recovered in urine within 24 h | Systemic side effects are extremely rare; drug acts locally in the colon |
| Distribution | Not systemically distributed; remains in GI lumen | No hepatic first-pass effect; no dose adjustment for organ impairment |
| Metabolism | Colonic bacteria ferment to lactic, acetic, and formic acids | Antibiotic co-therapy may reduce bacterial metabolism and drug efficacy |
| Elimination | Fecal (as organic acid metabolites); urinary excretion ≤3% | No renal or hepatic dose adjustment required; onset 24–48 h for laxative effect |
Side Effects
≥10%
Very Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Flatulence and gaseous distention | ~20% | Most prominent during first days of therapy; usually transient and diminishes with continued use |
| Abdominal cramping / discomfort | ~20% | Often co-occurs with bloating; may be reduced by taking with meals or starting at lower doses |
| Diarrhea (dose-related) | >10% | Considered an indication of excessive dosing; resolve promptly with dose reduction. Very common at higher doses (e.g., 9.7% at 39 g/day in one trial) |
1–10%
Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 1–5% | More common at initiation; can be mitigated by mixing dose with cold juice or water |
| Vomiting | 1–3% | Reported infrequently; if persistent, consider alternative laxative or route change |
| Belching / borborygmi | ~5% | Related to colonic gas production; typically self-limiting |
| Abdominal distension | 2–5% | Distinct from cramping; relates to gas accumulation in colon |
Serious
Serious (Regardless of Frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe dehydration with electrolyte derangement (hypokalemia, hypernatremia) | Uncommon | Days to weeks, usually with excessive dosing or diarrhea | Reduce dose or hold; IV fluid and electrolyte replacement; monitor potassium and sodium |
| Hypernatremia (isolated) | Rare | Days to weeks of therapy, particularly in elderly or debilitated patients | Check serum sodium; reduce or stop lactulose; correct free water deficit |
| Lactic acidosis | Very rare (case reports) | Variable | Discontinue immediately; supportive care; evaluate for alternative causes |
| Pneumatosis cystoides intestinalis | Very rare (case reports) | Weeks to months of use | Abdominal imaging; discontinue lactulose; usually resolves after cessation |
| Anaphylaxis / severe allergic reaction | Very rare | Any time | Emergency care; permanent discontinuation; document allergy |
Discontinuation
Discontinuation Rates
Constipation Trials
Low (formal rates not reported in FDA PI)
Top reasons: Diarrhea (dose-related), flatulence, abdominal cramping
Hepatic Encephalopathy
Low (generally well-tolerated long-term)
Top reasons: Persistent diarrhea, electrolyte disturbances, taste intolerance
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Intractable diarrhea despite dose reduction | Low (not formally quantified) | More likely with HE dosing; usually resolves with dose titration |
| Taste / palatability intolerance | Low | Sweet syrup taste is poorly tolerated by some; Kristalose powder may improve adherence |
| Excessive flatulence and bloating | Low | Often self-resolving after first week; rarely a sole reason for discontinuation |
Managing Diarrhea — The Most Important Side Effect
Diarrhea during lactulose therapy is a sign of overdosing, not an expected therapeutic effect. In patients with hepatic encephalopathy, uncorrected diarrhea leads to dehydration, hypokalemia, and hypernatremia — all of which can paradoxically worsen encephalopathy. The correct response is always dose reduction, not addition of an antidiarrheal agent.
Drug Interactions
Lactulose has negligible systemic absorption and is not metabolized by hepatic cytochrome P450 enzymes, so pharmacokinetic interactions are minimal. The clinically relevant interactions relate to its colonic mechanism of action and the osmotic/electrolyte effects of its laxative properties.
Major
Other Laxatives (during HE therapy)
MechanismCombined laxative effect produces loose stools independent of lactulose action
EffectFalsely suggests adequate lactulose dosing when ammonia reduction may be insufficient; risk of dehydration
ManagementAvoid concurrent laxatives during initial phase of HE treatment; if needed, reassess lactulose titration after discontinuing the other agent
FDA PI
Moderate
Neomycin and Other Oral Antibiotics
MechanismAntibiotic suppression of colonic bacteria that metabolize lactulose to active organic acids
EffectMay reduce lactulose efficacy by preventing colonic acidification; paradoxically, the combination is sometimes used clinically
ManagementMonitor stool pH and ammonia levels closely if combining; note that rifaximin has a favorable interaction profile and is the preferred antibiotic adjunct
FDA PI
Moderate
Non-absorbable Antacids (aluminum/magnesium hydroxide)
MechanismAlkalinization of colonic contents may counteract the pH-lowering action of lactulose metabolites
EffectPossible reduction in ammonia-trapping efficacy in HE management
ManagementAvoid concurrent administration when using lactulose for HE; separate doses by at least 2 hours if both necessary
FDA PI
Moderate
Loop and Thiazide Diuretics
MechanismAdditive potassium wasting when lactulose causes persistent diarrhea
EffectIncreased risk of hypokalemia, particularly dangerous in cirrhotic patients already prone to electrolyte disturbances
ManagementMonitor serum potassium regularly; supplement potassium as needed; consider spironolactone which is potassium-sparing
Lexicomp
Minor
Oral Medications (general)
MechanismIncreased GI transit time from osmotic laxation may reduce absorption of concurrently administered oral drugs
EffectTheoretically reduced bioavailability of drugs with narrow absorption windows
ManagementAdminister critical oral medications at least 2 hours before or after lactulose doses when using high-dose regimens
Clinical Practice
Minor
Blood Glucose Monitoring (diabetic patients)
MechanismLactulose solution contains small amounts of free galactose and lactose (<1.6 g and <1.2 g per 15 mL, respectively)
EffectMinimal impact on blood glucose in most patients; higher HE doses provide more sugar load
ManagementUse with caution in diabetics, particularly at high doses; monitor blood glucose
FDA PIMonitoring
-
Stool Output
Daily (HE) or weekly (constipation)
Routine Target 2–3 soft formed stools per day for HE; for constipation, assess frequency and consistency. Frank diarrhea indicates overdosing. -
Serum Electrolytes
Periodically (q6 months minimum for long-term use)
Routine Potassium, sodium, chloride, and bicarbonate. Particularly important in elderly or debilitated patients on prolonged therapy (>6 months). Monitor more frequently if diarrhea develops. -
Blood Ammonia
Baseline and as clinically indicated
Trigger-based Useful for guiding initial therapy in HE; however, clinical mental status assessment is more reliable than ammonia levels for ongoing dose titration. Do not chase ammonia numbers. -
Mental Status
Each encounter (HE patients)
Routine West Haven criteria or serial Psychometric Hepatic Encephalopathy Score (PHES) to track response. Improvement typically seen within 24–48 h of achieving target stool output. -
Hydration Status
Ongoing during therapy
Trigger-based Assess fluid intake and signs of dehydration (postural hypotension, reduced urine output, dry mucous membranes) especially in elderly patients and during diarrheal episodes. -
Blood Glucose
As indicated in diabetic patients
Trigger-based Higher lactulose doses (HE regimens) deliver more free sugars; monitor glycemic control in diabetic patients.
Contraindications & Cautions
Absolute Contraindications
- Galactosemia or requirement for a low-galactose diet: Lactulose solution contains less than 1.6 g galactose per 15 mL; patients with galactosemia cannot metabolize this sugar safely (FDA PI).
- Known hypersensitivity to lactulose or any component of the formulation.
- Intestinal obstruction: Osmotic laxation in the setting of mechanical bowel obstruction risks perforation.
Relative Contraindications (Specialist Input Recommended)
- Pending electrocautery procedures during colonoscopy or proctoscopy: Colonic bacterial fermentation of lactulose produces hydrogen gas, which theoretically could ignite during electrocautery. A thorough non-fermentable bowel preparation should be completed before proceeding.
- Severe dehydration or pre-existing electrolyte disturbances: Lactulose-induced diarrhea may exacerbate fluid and electrolyte deficits. Correct abnormalities before initiating therapy when possible.
Use with Caution
- Diabetes mellitus: The solution contains small amounts of free galactose and lactose. Although the caloric contribution is small at constipation doses, high-dose HE regimens may have a measurable glycemic impact.
- Elderly or debilitated patients: Increased susceptibility to dehydration and electrolyte disturbances (particularly hypernatremia and hypokalemia). Serum electrolytes should be measured periodically in patients on prolonged therapy exceeding six months.
- Infants: Risk of dehydration and hyponatremia; monitor fluid balance carefully and reduce dose at first sign of diarrhea.
FDA Safety Advisory
Electrocautery Risk During Endoscopic Procedures
Hydrogen gas accumulation from colonic fermentation of lactulose may pose an explosion risk during electrocautery. Patients on lactulose therapy who require proctoscopy or colonoscopy should undergo thorough bowel cleansing with a non-fermentable solution. Insufflation with CO2 rather than room air provides an additional safety measure.
Patient Counselling
Purpose of Therapy
Lactulose is a synthetic sugar solution that works in the large intestine. For constipation, it draws water into the bowel to soften stools and stimulate bowel movements. For liver-related brain fog (hepatic encephalopathy), it works by trapping and removing ammonia, a toxin that the damaged liver cannot clear on its own.
How to Take
Lactulose solution can be taken straight or mixed with half a glass of water, juice, or milk to improve the taste. The powder formulation (Kristalose) should be dissolved completely in approximately 120 mL (4 oz) of water before drinking. For constipation, take once daily, preferably at the same time each day. For hepatic encephalopathy, take multiple times daily as prescribed. Do not skip doses, as consistent use is essential for preventing confusion episodes.
Bloating and Gas
Tell patient
Gas and bloating are common during the first few days of treatment and usually settle within one to two weeks. Eating smaller, more frequent meals and avoiding gas-producing foods (beans, carbonated drinks) can help.
Call prescriber
If bloating is severe, persistent beyond two weeks, or accompanied by significant abdominal pain.
Diarrhea
Tell patient
The goal is 2–3 soft stools daily (for HE) or regular soft bowel movements (for constipation). Watery diarrhea means the dose is too high. Drink plenty of fluids if stools are loose. Do not take anti-diarrhea medicines without discussing with your doctor first.
Call prescriber
If diarrhea persists for more than 24 hours despite reducing the dose, or if you feel dizzy, lightheaded, or produce very little urine.
Sweet Taste / Palatability
Tell patient
Many people find the sweet taste of the liquid unpleasant. Mixing with cold water, unsweetened juice, or milk can help. The powder formulation (Kristalose) has a milder taste when dissolved in water and may be preferable for long-term use.
Call prescriber
If taste aversion is causing you to skip doses, discuss switching to the powder formulation.
Delayed Onset
Tell patient
When used for constipation, lactulose may take 24–48 hours to produce a bowel movement. Do not increase the dose on your own if it has not yet taken effect within one day.
Call prescriber
If there is no bowel movement after 48–72 hours despite taking the prescribed dose.
Hepatic Encephalopathy — Adherence
Tell patient
Even when feeling well, it is critical to continue taking lactulose as prescribed to prevent episodes of confusion. Stopping the medication can cause ammonia levels to rise and trigger an encephalopathy episode within days.
Call prescriber
If you notice increasing confusion, personality changes, trouble sleeping (day-night reversal), or hand tremors — these may signal rising ammonia levels. Family members should be educated to recognise these signs.
Storage
Tell patient
Store at room temperature (20–25 °C / 68–77 °F). Do not freeze. The solution may darken slightly over time — this is normal and does not affect its effectiveness. Discard if the solution becomes extremely dark or cloudy.
Call prescriber
If the medicine appears unusually dark, cloudy, or has an off odour, do not use it.
Sources
Regulatory (PI / SmPC)
- Lactulose Solution, USP — FDA-approved prescribing information (Xttrium Laboratories). DailyMed. DailyMed Label Primary source for constipation indication, dosing, adverse effects, and contraindications.
- Lactulose Solution (for PSE) — FDA-approved prescribing information (Apozeal Pharmaceuticals). DailyMed. DailyMed Label Source for hepatic encephalopathy indication, rectal dosing, and pediatric dosing information.
- Kristalose (lactulose for oral solution) — FDA-approved prescribing information (Cumberland Pharmaceuticals). FDA SPL Powder formulation label; source for Kristalose-specific dosing and galactose content data.
Key Clinical Trials
- Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009;137(3):885-891. DOI Landmark RCT demonstrating lactulose reduces recurrence of overt hepatic encephalopathy compared to placebo.
- Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-1081. DOI Pivotal trial establishing rifaximin plus lactulose as the preferred combination for secondary prophylaxis of HE.
- Uribe M, Campollo O, Vargas F, et al. Acidifying enemas (lactitol and lactulose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology. 1987;7(4):639-643. DOI Early controlled data supporting rectal lactulose enema efficacy in acute hepatic coma.
- Kasuga M, Tsukioka K, Onodera K, et al. Efficacy and safety of a crystalline lactulose preparation (SK-1202) in Japanese patients with chronic constipation. J Gastroenterol. 2019;54(6):530-540. DOI Dose-finding RCT providing incidence rates for diarrhea (9.7% at 39 g/day) and other GI adverse effects.
Guidelines
- Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by AASLD and EASL. Hepatology. 2014;60(2):715-735. DOI Joint society guideline establishing lactulose as first-line therapy for hepatic encephalopathy with graded evidence recommendations.
- Tabbers MM, DiLorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr. 2014;58(2):258-274. DOI Guidelines supporting lactulose as a first-line osmotic laxative option in pediatric constipation.
Mechanistic / Basic Science
- Avery GS, Davies EF, Brogden RN. Lactulose: a review of its therapeutic and pharmacological properties with particular reference to ammonia metabolism and its mode of action in portal systemic encephalopathy. Drugs. 1972;4(1):7-48. DOI Comprehensive early review establishing the mechanistic basis of lactulose in ammonia metabolism and colonic acidification.
- Vince AJ, Burridge SM. Ammonia production by intestinal bacteria: the effects of lactose, lactulose and glucose. J Med Microbiol. 1980;13(2):177-191. DOI Laboratory study demonstrating how lactulose reduces ammonia production by altering colonic bacterial metabolism.
Pharmacokinetics / Special Populations
- Kot TV, Pettit-Young NA. Lactulose in the management of constipation: a current review. Ann Pharmacother. 1992;26(10):1277-1282. DOI Clinical review covering lactulose pharmacokinetics, adverse effect profile, and practical use in constipation management.
- Lactulose. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2024 (updated Feb 28, 2024). NCBI Bookshelf Comprehensive, regularly updated resource covering lactulose pharmacology, dosing, and clinical considerations for special populations.